SMI‎ > ‎


Action Lonza SMI

Au prix de 72.10 CHF (22.12.2009) nous sommes optimiste pour Lonza avec un objectif de 82 CHF espéré avant mars 2010 et nous fixons un ordre de vente limite à 68 CHF.

"Profil de Lonza
Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Its products and services span its customers’ needs from research to final product manufacture. Lonza is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. (...) Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. Lonza is also a leading provider of value chemical and biotech ingredients to the nutrition, hygiene, preservation, agro and personal care markets.

Lonza is headquartered in Basel, Switzerland and is listed on the SIX Swiss Exchange. In 2008, Lonza had sales of CHF 2.937 billion."